The Real Drivers of GLP-1 Growth
Our Head of U.S. Pharma and Biotech Terence Flynn discusses how the rapid pace of adoption of weight management treatments could have far-reaching implications across healthcare, consumer behavior and global markets. Read more insights from Morgan Stanley. ----- Transcript ----- Welcome to Thoughts on the Market. I’m…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Thoughts on the Market →
Here's How the New Weight Loss Drugs Could Change Everything
The State of Weight-Loss Drugs
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Novo Nordisk, Eli Lilly and the GLP-1 economy
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.